Answers are grounded in this paper and cite their sources.
This work supports neoadjuvant TLR agonist-based immunotherapeutics as realistic options for immune activation in the TME and long-term metastatic protection in TNBC.
No takes yet. Share an insight, caveat, or question.
Zanker et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: